Table 3.
Anti-cancer potential of extracts or substances isolated from Inonotus obliquus tested on different tumor cell lines.
| CANCER CELL LINE | ASSAYS | REFERENCES |
|---|---|---|
| A549 human lung adenocarcinoma | LDH release | 28,95 |
| Caspase-3 activity | 67,95 | |
| DNA fragmentation | ||
| Cell viability | 28,32,49,67,68,95 | |
| Cell migration | 28 | |
| Cell proliferation | ||
| ROS production | 67 | |
| Cytotoxicity | 31 | |
| HeLa human cervical cancer | Cell viability | 49,51 |
| Caspase-3 activity | 51 | |
| Cell migration | ||
| 4T1 mouse mammary carcinoma | Cell viability | 47 |
| MCF-7 human breast cancer | Cell viability | 47,49,68 |
| AGS human gastric cancer | Cell viability | 49 |
| HEK-293 human embryonic kidney | Cell viability | 49 |
| PA-1 human ovarian teratocarcinoma | Cell viability | 32 |
| U937 human myeloid leukemia cell | Cell viability | 32 |
| HL-60 human myeloid leukemia | Cell viability | 32 |
| CACO-2 human colon carcinoma | Cell viability | 30 |
| LDH release | ||
| ROS production | ||
| Cell proliferation | ||
| HT-29 human colorectal adenocarcinoma | Cell viability | 28,46 |
| DNA synthesis | ||
| Cell proliferation | ||
| LDH release | 28 | |
| Cell migration | ||
| H1264 lung adenocarcinoma | LDH release | 95 |
| Caspase-3 activity | ||
| DNA fragmentation | ||
| Cell viability | ||
| HCT-116 human colon carcinoma | Cell viability | 45 |
| LDH release | ||
| Caspase-3 activity | ||
| H1299 human non-small cell lung cancer | LDH release | 95 |
| Caspase-3 activity | ||
| DNA fragmentation | ||
| Cell viability | ||
| B16–F10 murine skin melanoma | Cell viability | 44,68,93 |
| Caspase-3 activity | 44 | |
| Cell cycle inhibition | ||
| Cell migration | 93 | |
| Calu-6 human pulmonary adenocarcinoma | LDH release | 95 |
| Caspase-3 activity | ||
| DNA fragmentation | ||
| Cell viability | ||
| HEC-1B human endometrial adenocarcinoma | Cell viability | 68 |
| P388 mouse leukemia | Caspase-3 activity | 94 |
| Cell viability | ||
| DNA fragmentation | ||
| Fao rat hepatoma | Cell viability | 28 |
| Cell proliferation | ||
| LDH release | ||
| Cell migration | ||
| P19 mouse embryo teratocarcinoma | Cell viability | 28 |
| Cell proliferation | ||
| LDH release | ||
| Cell migration | ||
| C6 rat glioma | Cell viability | 28 |
| Cell proliferation | ||
| LDH release | ||
| Cell migration | ||
| Hep3B human hepatoma | Cell viability | 43,107 |
| Cell cycle inhibition | 43 | |
| HepG2 human hepatoma | Cell viability | 43,107 |
| Cell cycle inhibition | 43 | |
| ROS production | 108 | |
| Hur7 human hepatoma | Cell viability | 68 |
| KATO-III human stomach carcinoma | Cell viability | 68 |
| DLD-1 human colon carcinoma | DNA fragmentation | 40 |
| SGC-7901 human gastric carcinoma | Cell viability | 38 |
|
SK-OV3 human ovary adenocarcinoma |
Cell viability | 68 |
| SW156 kidney adenocarcinoma | Cell viability | 68 |
| SW620 human colorectal adenocarcinoma | Cell proliferation | 105 |